Welcome to Thoughts in the Market.

I'm Andrew Sheets, chief cross-ass strategist for Morgan Stanley Research.

And I'm Matthew Harrison, biotechnology analyst.

And today on the podcast, we'll be talking about progress on COVID-19 vaccinations and

the road to herd immunity.

It's Thursday, May 6th at 3pm in London.

And it's 11am in New York.

So Matt, I think we continue to be at a very interesting place with regards to the COVID-19

crisis.

Because on one hand, you've seen new lows and fatalities in the US.

If you look at the economic data, it's clearly getting a lot better.

And yet there's some very troubling news coming out of India.

We've seen a plateau in vaccinations in the US.

And people are still very worried about the prospects of new variants or what next

winter could look like.

So I like to try to run through some of those issues and how you're thinking about it

from a research perspective.

So let's start in the US.

We describe for us the next few months in the US in terms of who's left to be vaccinated.

And what are you seeing in terms of vaccination hesitancy?

So the US has reached about the mid 40% range of the eligible population.

And remember, the eligible population in the US is those over 16 years of age.

...